Opioids and motor complications in Parkinson's disease.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  TIPS - Trends in Pharmacological Sciences

• Publication date

  2006-10-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/J.TIPS.2006.08.002PMID 16908075
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetics of Parkinson disease: paradigm shifts and future prospects

  2006cited by this paper
• Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.

  2005cited by this paper
• Increased D1 dopamine receptor signaling in levodopa‐induced dyskinesia

  2005cited by this paper
• The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?

  2005cited by this paper
• New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity.

  2005cited by this paper
• A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers.

  2005cited by this paper
• Dyskinesias occur in response to saline and naltrexone alone after priming with combination of dopaminergic agents and naltrexone in the MPTP parkinsonian monkeys.

  2005cited by this paper
• Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.

  2005cited by this paper
• Opioid receptors.

  2004cited by this paper
• In Vivo Regulation of Extracellular Signal-Regulated Protein Kinase (ERK) and Protein Kinase B (Akt) Phosphorylation by Acute and Chronic Morphine

  2004cited by this paper
• Historical review: Molecular and cellular mechanisms of opiate and cocaine addiction.

  2004cited by this paper
• Regulation of Dopamine D1 Receptor Function by Physical Interaction with the NMDA Receptors

  2004cited by this paper
• The opioid agonist morphine decreases the dyskinetic response to dopaminergic agents in parkinsonian monkeys.

  2004cited by this paper
• Deep brain stimulation

  2004cited by this paper
• A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.

  2004cited by this paper
• Compensatory regulation of striatal neuropeptide gene expression occurs before changes in metabolic activity of basal ganglia nuclei.

  2003cited by this paper
• Parkinson's Disease Mechanisms and Models

  2003cited by this paper
• Presymptomatic compensation in Parkinson's disease is not dopamine-mediated.

  2003cited by this paper
• D1 Dopamine Receptor Supersensitivity in the Dopamine-Depleted Striatum Animal Model of Parkinson’s Disease

  2003cited by this paper
• Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease.

  2003cited by this paper
• Loss of bidirectional striatal synaptic plasticity in L-DOPA–induced dyskinesia

  2003cited by this paper
• Does this patient have Parkinson disease?

  2003cited by this paper
• Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems.

  2003cited by this paper
• Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey.

  2002cited by this paper
• Animal models of PD: pieces of the same puzzle?

  2002cited by this paper
• Nociceptin/orphanin FQ and opioid receptor‐like receptor mRNA expression in dopamine systems

  2002cited by this paper
• L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.

  2002cited by this paper
• Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets.

  2002cited by this paper
• Efferent projections from the striatal patch compartment: anterograde degeneration after selective ablation of neurons expressing mu-opioid receptor in rats.

  2002cited by this paper
• Presynaptic modulation of synaptic transmission by opioid receptor in rat subthalamic nucleus in vitro

  2002cited by this paper
• Increase of Preproenkephalin mRNA Levels in the Putamen of Parkinson Disease Patients with Levodopa‐Induced Dyskinesias

  2002cited by this paper
• μ- and δ-Opioid Receptor Antagonists Reduce Levodopa-Induced Dyskinesia in the MPTP-Lesioned Primate Model of Parkinson's Disease

  2001cited by this paper
• Persistent changes in striatal gene expression induced by long‐term l‐DOPA treatment in a rat model of Parkinson's disease

  2001cited by this paper
• The neurobiology of slow synaptic transmission.

  2001cited by this paper
• Preferential Cytoplasmic Localization of δ-Opioid Receptors in Rat Striatal Patches: Comparison with Plasmalemmal μ-Opioid Receptors

  2001cited by this paper
• Cellular and synaptic adaptations mediating opioid dependence.

  2001cited by this paper
• Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

  2001cited by this paper
• A Common Signaling Pathway for Striatal NMDA and Adenosine A2a Receptors: Implications for the Treatment of Parkinson's Disease

  2000cited by this paper
• Molecular basis of levodopa-induced dyskinesias.

  2000cited by this paper
• Dynorphin exerts both postsynaptic and presynaptic effects in the Globus pallidus of the rat.

  2000cited by this paper
• Dopamine-opioid interactions in the rat striatum: a modulatory role for dopamine D1 receptors in delta opioid receptor-mediated signal transduction.

  2000cited by this paper
• Organization of the basal ganglia: the importance of axonal collateralization.

  2000cited by this paper
• Functional changes of the basal ganglia circuitry in Parkinson's disease.

  2000cited by this paper
• Differential Regulation of Striatal Preproenkephalin and Preprotachykinin mRNA Levels in MPTP‐Lesioned Monkeys Chronically Treated with Dopamine D1 or D2 Receptor Agonists

  1999cited by this paper
• μ‐opioid and NMDA‐type glutamate receptors are often colocalized in spiny neurons within patches of the caudate‐putamen nucleus

  1999cited by this paper
• μ‐ and δ‐opioid receptor agonists inhibit DARPP‐32 phosphorylation in distinct populations of striatal projection neurons

  1999cited by this paper
• Pathophysiology of L-dopa-induced dyskinesias.

  1999cited by this paper
• Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: a 33P in situ hybridization study.

  1999cited by this paper
• Striatal Preproenkephalin Gene Expression Is Upregulated in Acute but Not Chronic Parkinsonian Monkeys: Implications for the Contribution of the Indirect Striatopallidal Circuit to Parkinsonian Symptomatology

  1999cited by this paper
• L‐DOPA‐induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin‐ and glutamic acid decarboxylase mRNA

  1998cited by this paper
• Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: contribution of calcium conductances.

  1998cited by this paper
• Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease.

  1998cited by this paper
• Ca2+ channel-regulated neuronal gene expression.

  1998cited by this paper
• Alterations in opioid receptor binding in Parkinson's disease patients with levodopa‐induced dyskinesias

  1997cited by this paper
• Consequences of Nigrostriatal Denervation on the Functioning of the Basal Ganglia in Human and Nonhuman Primates: An In Situ Hybridization Study of Cytochrome Oxidase Subunit I mRNA

  1997cited by this paper
• Pre- and postsynaptic inhibition by opioids in rat striatum

  1992cited by this paper
• Primate models of movement disorders of basal ganglia origin.

  1990cited by this paper
• Evidence for the presynaptic localization of opiate binding sites on striatal efferent fibers.

  1984cited by this paper

• Emerging Role of Tripartite Synaptic Transmission in the Pathomechanism of Autosomal-Dominant Sleep-Related Hypermotor Epilepsy

  2025cites this paper
• Subcortical Circuits Among Pedunculopontine Nucleus, Thalamus and Basal Ganglia Play Important Roles in Paroxysmal Arousal in Genetic Rat Models of Autosomal Dominant Sleep-Related Hypermotor Epilepsy

  2025cites this paper
• Distinct neurochemical influences on fMRI response polarity in the striatum

  2024cites this paper
• Differential effects of opioid receptor antagonism on the anti-dyskinetic and anti-parkinsonian effects of sub-anesthetic ketamine treatment in a preclinical model.

  2024cites this paper
• Neuromodulation in Parkinson’s disease targeting opioid and cannabinoid receptors, understanding the role of NLRP3 pathway: a novel therapeutic approach

  2023influential citation
• Disentangling dyskinesia from parkinsonism in motor structures of patients with schizophrenia

  2022cites this paper
• Loss of Corticostriatal Mu-Opioid Receptors in α-Synuclein Transgenic Mouse Brains

  2022influential citation
• New Insights into Pathogenesis of L-DOPA-Induced Dyskinesia.

  2021cites this paper
• Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia

  2020cites this paper
• Sedative drugs modulate the neuronal activity in the subthalamic nucleus of parkinsonian patients

  2020cites this paper
• δ-opioid receptor activation protects against Parkinson’s disease-related mitochondrial dysfunction by enhancing PINK1/Parkin-dependent mitophagy

  2020cites this paper
• Tapentadol Prevents Motor Impairments in a Mouse Model of Dyskinesia.

  2020cites this paper
• Identification of antiparkinsonian drugs in the 6-hydroxydopamine zebrafish model.

  2019cites this paper
• Construction of Parkinson's disease marker-based weighted protein-protein interaction network for prioritization of co-expressed genes.

  2019cites this paper
• The Basal Ganglia: More than just a switching device

  2018cites this paper
• The delta‐opioid receptor and Parkinson’s disease

  2018cites this paper
• The combination of the opioid glycopeptide MMP‐2200 and a NMDA receptor antagonist reduced l‐DOPA‐induced dyskinesia and MMP‐2200 by itself reduced dopamine receptor 2‐like agonist‐induced dyskinesia

  2018influential citation
• The Role of Human α7-Nicotinic Acetylcholine Receptors in Mediating Neuroprotective Action of Curcumin

  2018cites this paper
• Opioid system in L-DOPA-induced dyskinesia

  2017cites this paper
• Imaging in Parkinson's Disease.

  2017cites this paper
• Imaging in Parkinson's Disease.

  2017cites this paper
• Progressive Changes in MOR1 in the Striatum of the Heterozygous Q175 Knock-in Mouse Model of Huntington's Disease

  2016cites this paper
• Altérations du système de récompense dans la maladie de Parkinson : relation entre comportement et signatures moléculaires. : Neuropsychopharmacologie.

  2016cites this paper
• Molecular imaging of levodopa-induced dyskinesias

  2015cites this paper
• L'impact de la surexpression de pré-enképhaline striatale sur la dyskinésie induite par la L-DOPA dans la maladie de Parkinson

  2015influential citation
• The Delta-Opioid System in the Brain: A Neglected Element in Parkinson’s Disease?

  2015cites this paper
• Adverse Effects and Pharmacological Management of Newer Antidepressants - Focusing on Common but Under-Recognized Adverse Effect -

  2014cites this paper
• 새로운 항우울제의 부작용과 약물학적 처치

  2014cites this paper
• Acute Morphine Treatments Alleviate Tremor in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Monkeys

  2014cites this paper
• The Opioid System in Levodopa-Induced Dyskinesia

  2014cites this paper
• Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model

  2014cites this paper
• Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.

  2014cites this paper
• The effect of striatal pre‐enkephalin overexpression in the basal ganglia of the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mouse model of Parkinson's disease

  2014influential citation
• Multifunctional approach of L-Dopa induced dyskinesia pathophysiology in Parkinson’s disease : from the striatum to the whole brain

  2014cites this paper
• Striatal Pre-Enkephalin Overexpression Improves Huntington’s Disease Symptoms in the R6/2 Mouse Model of Huntington’s Disease

  2013cites this paper
• Response of striosomal opioid signaling to dopamine depletion in 6-hydroxydopamine-lesioned rat model of Parkinson's disease: a potential compensatory role

  2013influential citation
• Nur77 au sein des désordres dopaminergiques inhérents à la schizophrénie, la maladie de Parkinson ou la dépendance aux drogues d'abus

  2013cites this paper
• Non-analgesic effects of opioids: interactions between opioids and other drugs.

  2012cites this paper
• Distinct Neurogenomic States in Basal Ganglia Subregions Relate Differently to Singing Behavior in Songbirds

  2012cites this paper
• [Transcient improvement of extrapyramidal syndrome after general anaesthesia].

  2012cites this paper
• Effect of Chronic L-Dopa or Melatonin Treatments after Dopamine Deafferentation in Rats: Dyskinesia, Motor Performance, and Cytological Analysis

  2012cites this paper
• Influence of corticostriatal δ-opioid receptors on abnormal involuntary movements induced by L-DOPA in hemiparkinsonian rats.

  2012cites this paper
• Protein kinase C activity alters the effect of &mgr;-opioid receptors on inhibitory postsynaptic current in the striosomes

  2012cites this paper
• CNS penetration of the opioid glycopeptide MMP-2200: a microdialysis study.

  2012cites this paper
• Endogenous opioid systems

  2012cites this paper
• Amélioration transitoire d’un syndrome Parkinsonien après anesthésie générale

  2012cites this paper
• Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation

  2011cites this paper
• L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission

  2011cites this paper
• Effects of the novel glycopeptide opioid agonist MMP-2200 in preclinical models of Parkinson's disease.

  2011cites this paper
• Delta Opioid Receptor Function

  2011cites this paper
• Targeting nicotinic receptors for Parkinson's disease therapy.

  2011cites this paper
• Molecular mechanisms of l-DOPA-induced dyskinesia.

  2011cites this paper
• NEUROLOGIC DISEASE AND ANESTHESIA

  2010cites this paper
• Gene expression profiling in progressively MPTP-lesioned macaques reveals molecular pathways associated with sporadic Parkinson's disease.

  2010cites this paper
• TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.

  2009cites this paper
• The novel delta opioid receptor agonist UFP-512 dually modulates motor activity in hemiparkinsonian rats via control of the nigro-thalamic pathway.

  2009cites this paper
• Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway.

  2009cites this paper
• Author ' s personal copy INTERMITTENT DOPAMINERGIC STIMULATION CAUSES BEHAVIORAL SENSITIZATION IN THE ADDICTED BRAIN AND PARKINSONISM

  2009cites this paper
• Multiple roles for nicotine in Parkinson's disease.

  2009cites this paper
• Nicotine and Parkinson's disease: Implications for therapy

  2008cites this paper
• Parkinson's disease: Levodopa‐induced dyskinesia and signal transduction

  2008cites this paper
• Preventing and controlling dyskinesia in Parkinson's disease—A view of current knowledge and future opportunities

  2008cites this paper
• Consideraciones anestésicas en la enfermedad de Parkinson

  2008cites this paper
• Treatment of levodopa-induced dyskinesia

  2007cites this paper
• Compartment-Specific Modulation of GABAergic Synaptic Transmission by μ-Opioid Receptor in the Mouse Striatum with Green Fluorescent Protein-Expressing Dopamine Islands

  2007cites this paper
• Nicotine reduces levodopa‐induced dyskinesias in lesioned monkeys

  2007cites this paper
• The role of opioid receptor agonists and antagonists in the treatment of Parkinson’s disease

  2007cites this paper
• Provided for Non-commercial Research and Educational Use Only. Not for Reproduction, Distribution or Commercial Use

  year unknowninfluential citation